FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series B / Biotech startups that raised Series B in Switzerland

Biotech startups that raised Series B in Switzerland

Updated 16 Nov 2026

Reset
Biotech startups that raised Series B in Switzerland
One-time CSV
  • 31 funded companies, 20 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech--series-b~switzerland.csv31 rows × 18 columns
CompanyCityLast roundAmountDate
NovaGo TherapeuticsSchlierenSeries B$29.7M2026-08-31
Vaderis TherapeuticsBaselSeries B$152.0M2026-08-11
Windward BioBaselSeries B$165.0M2026-05-04
GlycoEraWädenswilSeries B$130.0M2025-05-27
Noema PharmaBaselSeries B$147.2M2024-12-11
Lymphatica MedtechEcublensSeries B$19.6M2024-10-08
CorFlow TherapeuticsBaarSeries B$48.5M2024-09-10
iOncturaGenevaSeries B$85.7M2024-06-20

8 rows of the CSV in 5 of its 18 columns.

31
Startups
$1.6B
Total raised
3
Funded in the last 12 months
$346.7M
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

18 of 31
18 rows
Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
NovaGo Therapeutics NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke. Biotech Schlieren Series B $29.7M 2026-08-31 $39.7M Kinled Holding, Pureos Bioventures 1 to 10 2015
Vaderis Therapeutics Vaderis Therapeutics develops targeted therapies for rare vascular diseases in clinical trials. Biotech Basel Series B $152.0M 2026-08-11 $170.6M Medicxi 11 to 50 2019
Windward Bio Windward Bio develops monoclonal antibodies for advanced immunological diseases. Biotech Basel Series B $165.0M 2026-05-04 $365.0M Qiming Venture Partners, OrbiMed, Novo Holdings +2 11 to 50 2024
GlycoEra GlycoEra researches and produces extracellular protein degraders for treating autoimmune diseases. Biotech Wädenswil Series B $130.0M 2025-05-27 $179.3M Sofinnova Partners, Bristol-Myers Squibb, 5AM Ventures +1 11 to 50 2020
Noema Pharma Noema Pharma develops therapies that treat disabling symptoms of brain and nervous system conditions. Biotech Basel Series B $147.2M 2024-12-11 $316.5M Polaris Partners, Sofinnova Partners, Invus +2 11 to 50 2019
CorFlow Therapeutics CorFlow Therapeutics develops proprietary technologies to diagnose and treat microvascular obstructions. Biotech Baar Series B $48.5M 2024-09-10 $66.1M Innosuisse, Unorthodox Ventures, Panakes Partners +2 11 to 50 2016
iOnctura iOnctura is a clinical-stage biotechnology company developing treatments for cancer. Biotech Geneva Series B $85.7M 2024-06-20 European Innovation Council, M Ventures, VI Partners +2 11 to 50 2017
Hemotune Hemotune develops a therapeutic blood purification platform for treating health conditions. Biotech Schlieren Series B $15.6M 2024-03-25 Venture Kick, Innosuisse, Gebert Rüf Stiftung 11 to 50 2016
MaxiVAX MaxiVAX is a Swiss clinical-stage biotechnology company. Biotech Geneva Series B $5.0M 2019-11-27 EIC Accelerator 1 to 10 2005
Amal Therapeutics Amal Therapeutics SA is a privately held Swiss and German biotech startup spun off from the University of Geneva. Biotech Geneva Series B $32.6M 2018-11-12 HTGF (High-Tech Gruenderfonds), Venture Kick, VI Partners +2 11 to 50 2012
Therachon Therachon is a global biotechnology company developing medicines for rare genetic diseases. Biotech Basel Series B $60.0M 2018-08-09 $100.0M Bpifrance, New Enterprise Associates, OrbiMed +2 1 to 10 2014
Cardiorentis Cardiorentis is a privately owned biopharmaceutical company. Biotech Zug Series B $60.4M 2016-01-10 HealthCare Royalty Partners 1 to 10 2010
Covagen Covagen develops protein-based therapeutics for inflammatory diseases and cancer. Biotech Schlieren Series B $66.1M 2013-12-09 Ventech, Novartis Venture Fund, Andera Partners +2 11 to 50 2007
Mind-NRG Mind-NRG develops peptidic neurotrophic factors for psychiatric and neurologic diseases. Biotech Geneva Series B $7.9M 2013-09-04 Index Ventures, Limburgse Reconversie Maatschappij 1 to 10 2010
Okairos Okairos develops genetic T-cell vaccines, including candidates targeting hepatitis C virus. Biotech Basel Series B $20.5M 2010-09-14 $30.1M EQT Life Sciences, Versant Ventures, Novartis Venture Fund +2 1 to 10 2007
ESBATech ESBATech develops fully human antibody fragments for therapeutic applications using the single-chain antibody framework. Biotech Schlieren Series B $22.0M 2008-08-07 Novartis Venture Fund, VI Partners, SV Health Investors +2 51 to 100 1998
Vivendy Therapeutics Vivendy Therapeutics develops enzyme replacement therapies. Biotech Basel Series B $30.5M 2008-06-23 EQT Life Sciences, BioMedPartners, TVM Capital +1 11 to 50 2006
PregLem PregLem is a Swiss biopharmaceutical company that develops and commercializes new drugs. Biotech Geneva Series B $32.2M 2007-12-04 $58.2M Sofinnova Partners, Sofinnova Investments, MVM Life Science Partners +1 11 to 50 2006

Table 1. Biotech startups that raised Series B in Switzerland: the 18 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 31.

Largest rounds

Last 12 months
# Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
1 Windward Bio Windward Bio develops monoclonal antibodies for advanced immunological diseases. Biotech Basel Series B $165.0M 2026-05-04 $365.0M Qiming Venture Partners, OrbiMed, Novo Holdings +2 11 to 50 2024
2 Vaderis Therapeutics Vaderis Therapeutics develops targeted therapies for rare vascular diseases in clinical trials. Biotech Basel Series B $152.0M 2026-08-11 $170.6M Medicxi 11 to 50 2019
3 NovaGo Therapeutics NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke. Biotech Schlieren Series B $29.7M 2026-08-31 $39.7M Kinled Holding, Pureos Bioventures 1 to 10 2015

Table 2. Biotech startups that raised Series B in Switzerland: the 3 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 Venture Kick Startup incubator Schlieren, Switzerland 4 13%
2 VI Partners Venture capital firm Altendorf, Switzerland 4 13%
3 Sofinnova Partners Venture capital firm Paris, France 3 10%
4 Innosuisse Government investment office Berne, Switzerland 3 10%
5 BioMedPartners Venture capital firm Basel, Switzerland 3 10%
6 Novartis Venture Fund Corporate venture arm Basel, Switzerland 3 10%
7 Novo Holdings Corporate venture arm Hellerup, Denmark 2 6% 1 Windward Bio
8 OrbiMed Private equity firm New York, United States 2 6% 1 Windward Bio
9 HTGF (High-Tech Gruenderfonds) Venture capital firm Bonn, Germany 2 6%
10 Boehringer Ingelheim Venture Fund Corporate venture arm Ingelheim Am Rhein, Germany 2 6%
11 Versant Ventures Venture capital firm Menlo Park, United States 2 6%
12 Andera Partners Private equity firm Paris, France 2 6%
13 Index Ventures Venture capital firm San Francisco, United States 2 6%
14 SV Health Investors Private equity firm Boston, United States 2 6%
15 EQT Life Sciences Private equity firm Amsterdam, The Netherlands 2 6%

Table 3. Biotech startups that raised Series B in Switzerland: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 30 97% $1.6B
Software 1 3% $4.4M
Education 1 3%

Table 4. Biotech startups that raised Series B in Switzerland by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series B 31 100% $26.0M

Table 5. Biotech startups that raised Series B in Switzerland by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Basel 7 23%
Geneva 5 16%
Schlieren 4 13%
Lausanne 3 10%
Zug 2 6%
Wädenswil 1 3%
Ecublens 1 3%
Baar 1 3%
Bioggio 1 3%
Windisch 1 3%
Zürich 1 3%
Epalinges 1 3%

Table 6. Biotech startups that raised Series B in Switzerland by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
August 2026 2 67% $181.7M
May 2026 1 33% $165.0M

Table 7. Biotech startups that raised Series B in Switzerland: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 3 10% $346.7M
2025 3 10% $206.0M
2024 5 16% $316.5M
2019 1 3% $5.0M
2018 2 6% $92.6M
2016 2 6% $118.0M

Table 8. Biotech startups that raised Series B in Switzerland by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 1 3%
2020 to 2022 2 6%
2015 to 2019 7 23%
2010 to 2014 7 23%
Before 2010 14 45%

Table 9. Biotech startups that raised Series B in Switzerland by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 12 39%
11 to 50 16 52%
51 to 100 2 6%
1,001 to 5,000 1 3%

Table 10. Biotech startups that raised Series B in Switzerland by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in Switzerland whose last round is Series B are on the list?
31, in the file dated 16 November 2026. 3 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 31 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series B in Switzerland: 31 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech at other stages in Switzerland

Other sectors that raised Series B in Switzerland

Cite: FundingWatcher, 31 biotech companies in Switzerland whose most recent round is Series B, 16 November 2026. https://fundingwatcher.com/startups/biotech/series-b/switzerland/